Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

By R. Rother, S. Rollins, C. Mojcik, R. Brodsky, L. Bell. Nature Biotechnology, 2007

746 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Complement System Part I – Molecular Mechanisms of Activation and Regulation (2015, background): “The therapeutic monoclonal antibody, Eculizumab, targets human C5 and blocks cleavage by C5 convertases (326).”
Therapeutic antibodies for autoimmunity and inflammation (2010, background): “Eculizumab lacks the ability to bind FcγRs and activate complement, which are common attributes for human IgG2 and IgG4, respectivel”